Arax Advisory Partners’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
Other funds holding KROS
NCM
O
MAP
Arax Advisory Partners's KROS Position: Q2 2026 in Review
Arax Advisory Partners increased its Keros Therapeutics (KROS) stake by 2,483% in Q2 2026, buying an estimated $108K and bringing the position to 10,047 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #2678.
Arax Advisory Partners first reported a position in KROS in Q2 2024 and has held it in 6 quarters since. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.
- Arax Advisory Partners held 10,047 shares of Keros Therapeutics worth $108K as of Q2 2026.
- Arax Advisory Partners bought 9,658 Keros Therapeutics shares in Q2 2026, an estimated $108K.
- Keros Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2678 holding.
- Arax Advisory Partners first reported a position in Keros Therapeutics in Q2 2024 and has held it in 6 quarters since.
- 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.